Clinical Overview
Blonanserin is an atypical antipsychotic indicated for the treatment of schizophrenia. Important Note: This medication is primarily available in Japan and South Korea and is not approved for use in the United States or most Western countries. It offers a unique receptor profile with potentially fewer metabolic side effects than some other atypical antipsychotics.
Primary Clinical Applications
Blonanserin is indicated for schizophrenia treatment in Japan and South Korea. It is particularly noted for its effectiveness in treating both positive and negative symptoms of schizophrenia with a relatively favorable side effect profile, including lower risk of metabolic effects and prolactin elevation.
Mechanism and Clinical Benefits
Blonanserin has high affinity for dopamine D2, D3, and serotonin 5-HT2A receptors with minimal affinity for histamine, muscarinic, or α-adrenergic receptors. This selective receptor profile contributes to its antipsychotic efficacy while potentially reducing sedation, weight gain, and metabolic side effects.
Clinical Advantages
Studies suggest blonanserin has lower propensity for metabolic side effects, weight gain, and prolactin elevation compared to some other atypical antipsychotics. It may be particularly suitable for patients concerned about metabolic complications or sexual side effects.
Prescribing Information
Dosing & Administration
Schizophrenia – Adults:
- Initial: 4 mg twice daily (8 mg/day)
- Titration: Increase by 4 mg/day at weekly intervals
- Maintenance: 8-24 mg daily in divided doses
- Maximum: 24 mg daily
Administration:
- Take with or without food
- Administer in divided doses (twice daily)
- Gradual dose titration to minimize side effects
Elderly:
- Start with lower doses
- Titrate more slowly based on tolerability
Indications
- Schizophrenia (Japan and South Korea approval)
- Treatment of positive and negative symptoms
Contraindications
- Known hypersensitivity to blonanserin
- Comatose states
- CNS depression from alcohol, barbiturates, or narcotics
Warnings & Precautions
- Availability: Not approved in United States or most Western countries
- Neuroleptic malignant syndrome: Rare but potentially fatal
- Tardive dyskinesia: Risk increases with duration of treatment
- QT prolongation: Monitor in patients with cardiac risk factors
- Seizures: Use caution in patients with seizure history
- Orthostatic hypotension: Monitor blood pressure
Drug Interactions
- CNS depressants: Enhanced sedation
- QT-prolonging drugs: Potential additive effects
- CYP3A4 inhibitors: May increase blonanserin levels
- Dopamine agonists: Antagonistic effects
Adverse Reactions
Common:
- Extrapyramidal symptoms, akathisia, insomnia, anxiety
Less Common:
- Sedation, dizziness, constipation, nausea
Metabolic:
- Lower incidence of weight gain and metabolic effects
Special Populations
- Availability: Limited to Japan and South Korea
- Pregnancy: Use only if benefits outweigh risks
- Elderly: Lower starting doses recommended
- Hepatic impairment: Use with caution, consider dose reduction
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
